Trial Profile
Long-Term Safety and Efficacy Evaluation of Vatiquinone (EPI-743) in Children With Leigh Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Vatiquinone (Primary) ; Vatiquinone (Primary)
- Indications Leigh disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioElectron Technology; PTC Therapeutics
- 29 Nov 2023 Status changed from active, no longer recruiting to completed.
- 12 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Oct 2023.
- 12 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Oct 2023.